1Dunn GP,Old LJ,Schreiber RD. The immunobiology of cancer immunosurveillanee and immunoediting[J].Immunity,2004,(02):137-148.doi:10.1016/j.immuni.2004.07.017.
2Fishelson Z,Donin N,Zell S. Obstacles to cancer immunotherapy:expression of membrane complement regulatory proteins (mCRPs) in tumors[J].Molecular Immunology,2003,(2/4):109-123.
3De Nardo C,Fonsatti E,Sigalotti L. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells[J].Journal of Cellular Physiology,2002,(02):200-206.
4Lukacik P,Roversi P,White J. Complement regulation at the molecular level:the structure of decay-accelerating factor[J].Proceedings of the National Academy of Sciences(USA),2004,(05):1279-1284.
5Ravindranath NM,Shuler C. Cell-surface density of complement restriction factors (CD46,CD55,and CD59):oral squamous cell carcinoma versus other solid rumors[J].Oral Stag Oral Med Oral Pathol Oral Radiol Ended,2007,(02):231-239.
8Tae-Hwa Baek,Joo-Heon Kim,Mee-Ja Park. The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients[J].Korean Journal of Plant Pathology,2011,(05):445-454.
10Mustafa T,Klonisch T,Hombach-Klonisch S. Expression of CD97 and CD55 in human medullary thyroid carcinomas[J].International Journal of Oncology,2004,(02):285-294.
4Ikeda J, Morii E, Liu Y, etal. Prognostic significance of CD55 expres sion in breast cancer[J]. Clin Cancer Res, 2008, 14(15): 4780-4786.
5Christophe G, Min HH, Emmanuelle C, etal. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5): 555-567.
6Spendlove I, Ramage JM, Bradley R, et al. Complement decay ac celerating factor (DAF)/CD55 in cancer[J]. Cancer Immunol Immunother, 2006, 55(8): 987 995.
7Koretz K, Brtiderlein S, Herme C, et al. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas[J]. BrJ Cancer, 1992, 66(5): 810-814.
8Madjd Z, Durrant LG, Bradley R, etal. Loss of CD55 is associated with aggressive breast tumors[J]. Clin Cancer Res, 2004, 10(8): 2797-2803.
9Chute JP, Muramoto C,G, WbitesJdes J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human bematopoietic stem cells[J]. Proc Natl Acad Sci USA, 2008, ]03 (31) : 11707-11712.
10[1]Schmitt C A,Schwaeble W,Wittig B M,et al.Expression and regulation by interferon gamma of the membrane-bound complement regulators CD46 (MCP),CD55(DAF) and CD59 in gastrointestinal tumours[J].Eur J Cancer,1999,35 (1):117-124.
1Zhao L, Xie F* Li H, et al. Combating non-Hodgkin lymphomaby targeting both CD20 and HLA-DR through CD20-243 Cross-Mab[J]. MAbs,2014,6(3) :739-747.
2Zhao L, T ong Q, Qian W, et al. Eradication of non-Hodgkin lym-phoma through the induction of tumor-specific T-cell immunityby CD20-Flex BiFP[J]. Blood,2013 ,122(26) :4230-4236.
3Wang SY,Racila E,Taylor RP,et al. NK-cell activation and an-tibody-dependent cellular cytotoxicity induced by rituximab-coa-ted target cells is inhibited by the C3b component of complement[J]. Blood,2008,111(3):1456-1463.
4Karavitis J,Zhang M. COX2 regulation of breast cancer bone metas-tasis[J]. Oncoimmunology,2013,2(3):123-129.
5Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy [J ]. Cancer Res,2007,67( 3) : 1270-1281.
6Calcagno A’Rostagno R,Di Perri G. Anti-CD20 antibody thera-py for B-cell lymphomas[J]. N Engl J Med, 2012,367(9):877-[8] Rezvani AR,Maloney DG. Rituximab resistance[J]. Best PractRes Clin Haematol,2011,24(2) :203-216.
7Rezvani AR,Maloney DG. Rituximab resistance[J].Best Pract Res Clin Haematol,2011,24(2) ..203-216.
8Zhang C,Liu HF, Chen XH, et al. Is splenectomy necessary forimmune thrombocytopenic purpura. The role of rituximab in pa-tients with corticosteroid resistance in a single-center experience[J]. Clin Ther,2014,36(3) :385-388.
9Verbrugge SE,A1 M, Assaraf YG,et al. Overcoming bortezomibresistance in human B cells by anti-CD20/rituximab-mediatedcomplement-dependent cytotoxicity and epoxy ketone-based irre-versible proteasome inhibitors[J]. Exp Hematol Oncol, 2013, 2(1):2.
